MktsMarkets

Bolt Biotherapeutics, Inc.
NASDAQ: BOLTKey statistics
BOLT News
Stories mentioning BOLT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 26.00 | 2,500 | 2,169 | 1,804 | 1,222 | 0.00 | 1,141 | 1,275 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 4,829 | 4,988 | 6,535 | 7,498 | 9,512 | 11,722 | 13,785 | 15,433 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 7,627 | 9,585 | 9,872 | 11,014 | 13,337 | 16,916 | 17,584 | 23,872 |
| Operating Income (Loss) | (7,601) | (7,085) | (7,703) | (9,210) | (12,115) | (16,916) | (16,443) | (22,597) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (7,244) | (6,631) | (7,144) | (8,561) | (11,040) | (15,936) | (15,176) | (21,195) |
| Earnings Per Share (Basic) | (4.31) | (3.55) | (3.72) | (4.46) | (5.76) | (8.35) | (7.93) | (11.12) |
| Earnings Per Share (Diluted) | (4.31) | (3.55) | (3.72) | (4.46) | (5.76) | (8.35) | (7.93) | (11.12) |
| Weighted Average Shares Outstanding (Basic) | 1,680 | 1,870 | 1,919 | 1,918 | 1,917 | 1,909 | 1,913 | 1,906 |
| Weighted Average Shares Outstanding (Diluted) | 1,680 | 1,870 | 1,919 | 1,918 | 1,917 | 1,909 | 1,913 | 1,906 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About BOLT
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) is a stock listed on the Nasdaq Stock Market under the ticker symbol BOLT. It last traded at $5.10 (Nov 18, 2026, 4:00 PM ET), down 9.7% on the day. That gives Bolt Biotherapeutics a market capitalisation of $14.7M.
Over the past 52 weeks BOLT has traded between $3.10 and $7.78.
Revenue for the quarter ended Mar 31, 2026 was $26.0K; a net loss of $7.2M. Revenue was down 97.9% from $1.2M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $26.0K | -$7.2M | -27861.5% |
| Dec 31, 2025 | $2.5M | -$6.6M | -265.2% |
| Sep 30, 2025 | $2.2M | -$7.1M | -329.4% |
| Jun 30, 2025 | $1.8M | -$8.6M | -474.6% |
From Bolt Biotherapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…